Welcome to our dedicated page for Enzolytics news (Ticker: ENZC), a resource for investors and traders seeking the latest updates and insights on Enzolytics stock.
Enzolytics, Inc. (ENZC) operates at the intersection of healthcare innovation and commercial strategy, focusing on medical device licensing, diagnostic technologies, and science-backed nutraceuticals. This news hub provides investors and industry observers with verified updates about the company’s strategic initiatives, intellectual property developments, and market expansions.
Our curated collection offers immediate access to ENZC’s press releases, including details on licensing agreements, acquisition strategies, and research advancements in immunotherapy and medical testing. Users will find updates on regulatory milestones, partnership announcements, and product distribution channels, all essential for understanding the company’s evolving role in healthcare innovation.
This resource is designed for efficient tracking of ENZC’s multifaceted operations, from its patented drug delivery systems to its defense of intellectual property in litigation matters. The content reflects the company’s commitment to merging scientific rigor with commercial viability across medical devices, bioactive compounds, and diagnostic solutions.
Bookmark this page for streamlined access to Enzolytics’ official communications, ensuring you remain informed about its progress in converting research into market-ready health technologies. Regular updates provide transparency into ENZC’s governance decisions and collaborative ventures within the global healthcare ecosystem.
Enzolytics, Inc. (ENZC) announced the establishment of International Medical Partners (IMPL), a Bulgarian LLC, in which it holds a 50% stake. The venture aims to fund clinical trials for ENZC’s patented ITV-1 therapeutics targeting HIV, adhering to European Medicine Agency (EMA) standards. The company expects EMA approval to facilitate FDA recognition as part of a Mutual Recognition Agreement. Enzolytics is preparing its financial statements for OTCQB submission, highlighting ongoing audits and filing deadlines for previous reports.
Enzolytics, Inc. (OTC PINK:ENZC) announced promising results from an in vitro study of its ITV-1/IPF peptide treatment against human coronavirus 229E (HCoV-229E). The study showed ITV-1's efficacy was 65%, compared to 75.5% for Tamiflu, but with 20-fold lower toxicity. Conducted by Professor Petia Genova-Kalou in Bulgaria, the study paves the way for further clinical trials to explore ITV-1's therapeutic potential. Enzolytics continues its commitment to develop innovative treatments for infectious diseases.
Enzolytics Inc. (OTC PINK:ENZC) has filed a provisional patent for a treatment of Multiple Sclerosis, confirmed by the U.S. Patent Office on December 9, 2020. Developed by CSO Harry Zhabilov, the patent includes compositions for treating various disorders, including immune deficiencies and viral infections. This innovation is set to complement ongoing developments in monoclonal antibodies against HIV and the Coronavirus at Texas A & M University's facility. Management emphasizes a commitment to expanding its pipeline for serious illnesses.
Enzolytics, Inc. (ENZC) has successfully merged with BioClonetics Immunotherapeutics on December 1, 2020, coinciding with World AIDS Day. This strategic merger enhances Enzolytics' capabilities in developing therapies for HIV and the Coronavirus. The patented antiviral peptide, ITV-1, has shown promising results in clinical trials, with 68% of HIV patients experiencing improved immune parameters. Additionally, Enzolytics is advancing fully human monoclonal antibodies, which have neutralized over 95% of HIV strains in tests. Future studies are planned in France and Italy to further validate these therapies.
Enzolytics, Inc. (OTC PINK:ENZC) announced the appointment of Dr. Ronald Moss to its Medical Advisory Board, enhancing its expertise in drug development for infectious diseases. Dr. Moss has over 25 years of executive and clinical experience in biotechnology, specifically in guiding clinical trials. The company has secured $500,000 in funding to support its combined operations and therapeutic development plans. Enzolytics is actively working to update its financial filings and aims to bring its technology, including the ITV-1 anti-HIV treatment, to market.
Enzolytics has appointed Charles Cotropia as CEO and Harry Zhabilov as CSO as part of a strategic move following their merger with BioClonetics. The company has secured $500,000 in funding to support initial operations aimed at developing effective therapeutics against infectious diseases, specifically targeting HIV and SARS-CoV-2. ENZC has also started bringing its financial filings up to date and plans to meet with a GMP manufacturer soon. The merger is expected to enhance the value of ENZC through combined technologies.
Enzolytics, Inc. (OTC PINK: ENZC) shared an update regarding its merger with BioClonetics Immunotherapeutics, Inc. The companies aim to combine technologies to address HIV and COVID-19, focusing on developing therapeutics against these infectious diseases. Enzolytics will test its ITV-1 peptide alongside BioClonetics' monoclonal antibodies, targeting immutable sites on the viruses. The merger, expected soon, will lead to leadership changes within the new entity. Additionally, ENZC plans to enhance its OTC Markets membership and engage a GMP manufacturer.
Enzolytics, Inc. (OTC PINK:ENZC) announced a binding letter of intent to merge with BioClonetics Immunotherapeutics, Inc. (BCLS), a Dallas-based biotech firm. This merger focuses on the development of a monoclonal antibody effective against over 95% of HIV-1 strains. The combined research will evaluate synergies between Enzolytics' ITV-1 therapeutic and BioClonetics' Clone 3 antibodies. Leadership changes are anticipated with Charles Cotropia becoming CEO. The merger aims to enhance both companies' capabilities in combating infectious diseases.
Enzolytics, Inc. (OTC PINK:ENZC) announced the appointment of Charles Cotropia to its Board of Directors as part of a planned merger with BioClonetics Immunotherapeutics, Inc. The merger aims to expedite due diligence leading to definitive agreements. Harry Zhabilov, CEO of ENZC, will join BioClonetics' Board as well. BioClonetics is developing a monoclonal antibody that has shown effectiveness against over 95% of HIV-1 strains. The companies plan joint studies, with future testing expected at the California National Primate Research Center.
Enzolytics, Inc. (OTC PINK:ENZC) has executed a non-binding letter of intent to merge with BioClonetics Immunotherapeutics, Inc. This merger aims to combine their technologies in developing monoclonal antibodies to combat HIV. BioClonetics is in final testing of its anti-HIV monoclonal antibody, Clone 3, showing efficacy against over 95% of HIV-1 strains. Additionally, they are exploring funding opportunities for anti-SARS-CoV-2 antibodies. ENZC plans to advance its flagship compound, ITV-1, towards FDA approval, enhancing its ability to treat infectious diseases.
